ScreenerHero

BIOABioAge Labs Inc. Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · bioagelabs.com
9.480USD-11.81%Mkt Cap: 435.10M $P/E: —

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to iden…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap435.10M $
Enterprise Value128.83M $
Revenue (TTM)10.36M $
Gross Profit-77.43M $
Net Income (TTM)-80.61M $
Revenue/Share0.2600 USD
Last Price9.480 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.11
PEG—
EV/EBITDA-1.22
EV/Revenue12.44
P/S42.95
P/B1.18
EPS (TTM)-2.15
EPS (Forward)-2.36
52W Range
4.38024% of range25.95
52W High25.95 USD
52W Low4.380 USD
Profitability
Gross Margin0.00%
Oper. Margin-1196.78%
EBITDA Margin0.00%
Profit Margin-896.11%
ROE-29.63%
ROA-27.33%
Growth
Revenue Growth1.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-81.63M $
CapEx (TTM)719.00K $
FCF Margin-560.76%
FCF Yield-13.35%
Net Debt-315.91M $
Net Debt/EBITDA2.98
Balance Sheet
Debt/Equity0.02
Current Ratio17.19
Quick Ratio16.75
Book Value/Sh8.190 USD
Cash/Share6.945 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)35.63 USD
Upside (mean)+275.8%
Target Range20.00 USD – 73.00 USD
$20.00+275.8% to mean$73.00
# Analysts8
Ownership
Shares Out.45.90M
Float39.19M
Insiders2.36%
Institutions90.44%
Short Interest
Short Ratio2.6d
Short % Float6.29%
Short % Out.5.59%
Shares Short2.57M
Short (prev mo.)3.74M
Technical
SMA 5018.75 (-49.4%)
SMA 20016.82 (-43.6%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)1.09M
Avg Vol (10d)624.42K
Technical Indicators
RSI (14)29.9
MACD-2.7205
MACD Signal-2.7153
MACD Hist.-0.0052
BB Upper22.88 USD
BB Middle12.96 USD
BB Lower3.044 USD
BB Width153.03%
ATR (14)1.352 USD
Vol Ratio (20d)0.33x